Study wrapper · #752
A mitochondrial-derived peptide MOTS-c contributes to the protective effect against brain injury associated with LPS-induced sepsis by strengthening the blood-brain barrier's ultrastructure.
Editor's note
In a mouse model of LPS-induced sepsis, researchers report that MOTS-c pretreatment improved survival and sepsis scores, reduced brain-tissue damage and neuroinflammation, and limited blood-brain-barrier permeability, with corresponding changes in barrier-related proteins and neurotrophic factors. This is a single-model preclinical study using pretreatment before sepsis induction, which is mechanistically informative but far from a clinical scenario. These are preclinical findings; human data are needed before any clinical conclusions can be drawn. It extends MOTS-c's anti-inflammatory, tissue-protective profile into sepsis-associated brain injury, consistent with its broader animal literature, but the protective framing rests on this one dataset and a prophylactic dosing design that does not mirror how sepsis presents clinically.
Plain-language abstract
Severe infection (sepsis) can injure the brain, partly by inflaming it and weakening the blood-brain barrier, the protective lining around brain blood vessels. Researchers tested MOTS-c, a mitochondria-derived peptide, in mice given a bacterial toxin (LPS) to trigger sepsis. Mice received MOTS-c four hours before sepsis was induced. Those given MOTS-c survived more often, had lower sepsis-severity scores, less brain damage, and reduced inflammation. MOTS-c also helped keep the blood-brain barrier intact, restoring protective proteins and boosting nerve-supporting factors. Because MOTS-c was given before the infection and the study used only mice, it cannot show how MOTS-c would help people who already have sepsis, and human studies would be needed. The findings fit a broader pattern of MOTS-c reducing inflammation and protecting tissue, here applied to the brain during severe infection.